Overall, these results reveal that BCAS3, an important substrate‐specific adaptor for CRL4A to regulate the p53 stability, acts as a novel prognostic marker and guides chemotherapy regimens for patients with breast cancer. Here, BCAS3 is linked to breast carcinoma.